- Home
- LFST vs AGIO Comparison
LFST vs AGIO Comparison
Compare LFST & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFST
- AGIO
- Stock Information
- Founded
- LFST 2015
- AGIO 2007
- Country
- LFST United States
- AGIO United States
- Employees
- LFST N/A
- AGIO N/A
- Industry
- LFST Medical/Nursing Services
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- LFST Health Care
- AGIO Health Care
- Exchange
- LFST Nasdaq
- AGIO Nasdaq
- Market Cap
- LFST 2.9B
- AGIO 2.4B
- IPO Year
- LFST 2021
- AGIO 2013
- Fundamental
- Price
- LFST $7.29
- AGIO $35.42
- Analyst Decision
- LFST Buy
- AGIO Buy
- Analyst Count
- LFST 5
- AGIO 7
- Target Price
- LFST $8.70
- AGIO $56.33
- AVG Volume (30 Days)
- LFST 1.5M
- AGIO 1.1M
- Earning Date
- LFST 11-07-2024
- AGIO 02-13-2025
- Dividend Yield
- LFST N/A
- AGIO N/A
- EPS Growth
- LFST N/A
- AGIO N/A
- EPS
- LFST N/A
- AGIO 11.80
- Revenue
- LFST $1,206,093,000.00
- AGIO $32,871,000.00
- Revenue This Year
- LFST $19.26
- AGIO $33.38
- Revenue Next Year
- LFST $12.47
- AGIO $163.06
- P/E Ratio
- LFST N/A
- AGIO $3.00
- Revenue Growth
- LFST 20.08
- AGIO 36.79
- 52 Week Low
- LFST $4.64
- AGIO $20.96
- 52 Week High
- LFST $9.20
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- LFST 50.37
- AGIO 28.75
- Support Level
- LFST $7.03
- AGIO $37.20
- Resistance Level
- LFST $7.81
- AGIO $44.46
- Average True Range (ATR)
- LFST 0.32
- AGIO 4.27
- MACD
- LFST -0.03
- AGIO -2.06
- Stochastic Oscillator
- LFST 41.81
- AGIO 1.06
About LFST LifeStance Health Group Inc.
LifeStance Health Group Inc is a mental healthcare company focused on providing evidence-based, medically driven treatment services for children, adolescents, and adults suffering from a variety of mental health issues in an outpatient care setting, both in-person and through its digital health telemedicine offering.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.